Letter to the Editor
Split Viewer
Korean J Hematol 2011; 46(3):
Published online September 30, 2011
https://doi.org/10.5045/kjh.2011.46.3.207
© The Korean Society of Hematology
A controversial conclusion regarding primary extranodal diffuse large B-cell lymphoma
Correspondence to : Correspondence to Department of Internal Medicine, College of Medicine, Soonchunhyang University, 1174 Jung-dong, Wonmi-gu, Bucheon 420-767, Korea. Tel: +82-32-621-5185, skpark@schmc.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
REFERENCES
- Jang, G, Yoon, DH, Kim, S, et al. Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma. Korean J Hematol, 2011;46;103-110.
- Krol, AD, le Cessie, S, Snijder, S, et al. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol, 2003;14;131-139.
- Cavalli F, Stein H, Zucca E. Extranodal lymphomas: pathology and managemen. London, UK: Informa Healthcare; 2008. p. 3-9.
- López-Guillermo, A, Colomo, L, Jiménez, M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol, 2005;23;2797-2804.
- Møller, MB, Pedersen, NT, Christensen, BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br J Haematol, 2004;124;151-159.
PDF
Standard view
Export citation
Share Article
Letter to the Editor
Korean J Hematol 2011; 46(3): 207-208
Published online September 30, 2011 https://doi.org/10.5045/kjh.2011.46.3.207
Copyright © The Korean Society of Hematology.
A controversial conclusion regarding primary extranodal diffuse large B-cell lymphoma
Seong Kyu Park, M.D.*, Jina Yun, M.D., Se Hyung Kim, M.D., and Dae Sik Hong, M.D.
Correspondence to: Correspondence to Department of Internal Medicine, College of Medicine, Soonchunhyang University, 1174 Jung-dong, Wonmi-gu, Bucheon 420-767, Korea. Tel: +82-32-621-5185, skpark@schmc.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
- Jang, G, Yoon, DH, Kim, S, et al. Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma. Korean J Hematol, 2011;46;103-110.
- Krol, AD, le Cessie, S, Snijder, S, et al. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol, 2003;14;131-139.
- Cavalli F, Stein H, Zucca E. Extranodal lymphomas: pathology and managemen. London, UK: Informa Healthcare; 2008. p. 3-9.
- López-Guillermo, A, Colomo, L, Jiménez, M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol, 2005;23;2797-2804.
- Møller, MB, Pedersen, NT, Christensen, BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br J Haematol, 2004;124;151-159.
Previous Article
